Finally, and partially due to the prolonged time span of our retrospective dataset, we were unable to reliably capture prognostic molecular markers including wild-type versus mutant isocitrate dehydrogenase status, as well as promoter methylation status of O (Bloch et al., 2017)-methylguanine-DNA methyltransferase that have emerged as major prognostic factors of GBM patient OS (Hegi et al., 2005; SongTao et al., 2012). The gene discussed is IDH3A; the disease is glioblastoma.